Agenus Inc (AGEN)
12.54
-0.70
(-5.32%)
USD |
NASDAQ |
May 02, 15:36
Agenus Cash from Financing (Quarterly): 7.315M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 7.315M |
| September 30, 2023 | 18.04M |
| June 30, 2023 | 38.26M |
| March 31, 2023 | 56.25M |
| December 31, 2022 | 23.77M |
| September 30, 2022 | 28.22M |
| June 30, 2022 | 27.80M |
| March 31, 2022 | 16.04M |
| December 31, 2021 | 71.60M |
| September 30, 2021 | 78.90M |
| June 30, 2021 | 11.79M |
| March 31, 2021 | 62.96M |
| December 31, 2020 | 24.65M |
| September 30, 2020 | 67.28M |
| June 30, 2020 | 26.31M |
| March 31, 2020 | 65.61M |
| December 31, 2019 | 1.268M |
| September 30, 2019 | 0.034M |
| June 30, 2019 | -0.076M |
| March 31, 2019 | 30.10M |
| December 31, 2018 | 43.43M |
| September 30, 2018 | 28.49M |
| June 30, 2018 | 22.57M |
| March 31, 2018 | 33.79M |
| December 31, 2017 | 16.77M |
| Date | Value |
|---|---|
| September 30, 2017 | 0.4078M |
| June 30, 2017 | 1.285M |
| March 31, 2017 | 62.07M |
| December 31, 2016 | 2.186M |
| September 30, 2016 | 0.5731M |
| June 30, 2016 | -4.657M |
| March 31, 2016 | -0.5629M |
| December 31, 2015 | 0.2119M |
| September 30, 2015 | 78.50M |
| June 30, 2015 | 74.77M |
| March 31, 2015 | 36.10M |
| December 31, 2014 | -0.7316M |
| September 30, 2014 | -1.644M |
| June 30, 2014 | -0.7229M |
| March 31, 2014 | 55.91M |
| December 31, 2013 | 2.758M |
| September 30, 2013 | 20.90M |
| June 30, 2013 | 2.108M |
| March 31, 2013 | 0.0184M |
| December 31, 2012 | -0.0098M |
| September 30, 2012 | 2.973M |
| June 30, 2012 | 4.282M |
| March 31, 2012 | 2.566M |
| December 31, 2011 | 0.1954M |
| September 30, 2011 | 6.114M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.076M
Minimum
Jun 2019
78.90M
Maximum
Sep 2021
32.95M
Average
26.31M
Median
Jun 2020
Cash from Financing (Quarterly) Benchmarks
| Protalix BioTherapeutics Inc | 0.00 |
| InfuSystems Holdings Inc | -3.544M |
| PAVmed Inc | 5.288M |
| Allogene Therapeutics Inc | 0.155M |
| Pfizer Inc | 5.442B |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -40.40M |
| Cash from Investing (Quarterly) | 2.824M |
| Free Cash Flow | -234.16M |
| Free Cash Flow Per Share (Quarterly) | -2.116 |
| Free Cash Flow to Equity (Quarterly) | -40.43M |
| Free Cash Flow Yield | -104.4% |